H

Huakang Biomedical Holdings Co Ltd
HKEX:8622

Watchlist Manager
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Watchlist
Price: 0.176 HKD 7.32% Market Closed
Market Cap: 88.1m HKD
Have any thoughts about
Huakang Biomedical Holdings Co Ltd?
Write Note
Section:
 

Relative Value

8622 doesn't have a meaningful market cap.

The Relative Value of one Huakang Biomedical Holdings Co Ltd stock under the Base Case scenario is 0.097 HKD. Compared to the current market price of 0.176 HKD, Huakang Biomedical Holdings Co Ltd is Overvalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
0.097 HKD
Overvaluation 45%
Relative Value
Price
H
Worst Case
Base Case
Best Case

Valuation Multiples

3.3
P/S
P/S
Price to Sales
3.3
vs History
9
vs Industry
51
Median 3Y
2.7
Median 5Y
2.3
Industry
2.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-17.6
Median 5Y
-12.4
Industry
23
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
14
Median 3Y
-30
Median 5Y
-30
Industry
14.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
21
Median 3Y
-22
Median 5Y
-22
Industry
20
More Details
1.5
P/B
P/B
Price to Book Value
1.5
vs History
9
vs Industry
66
Median 3Y
1.2
Median 5Y
1.1
Industry
2.2
More Details
1.6
EV/S
EV/S
Enterprise Value to Sales
1.6
vs History
11
vs Industry
77
Median 3Y
1.3
Median 5Y
1
Industry
2.4
More Details
2.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.5
vs History
12
vs Industry
81
Median 3Y
2.1
Median 5Y
1.4
Industry
5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-8
Median 5Y
-5.3
Industry
12.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-5.2
Industry
17.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
44
Median 3Y
-15.3
Median 5Y
-4.4
Industry
14
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
38
Median 3Y
-8.8
Median 5Y
-2.7
Industry
18.2
More Details
1.4
EV/IC
EV/IC
Enterprise Value to IC
1.4
vs History
11
vs Industry
78
Median 3Y
1.2
Median 5Y
0.8
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Huakang Biomedical Holdings Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
Huakang Biomedical Holdings Co Ltd
HKEX:8622
82.1m HKD 3.3 -13.6 -6.3 -6.3
JP
Hoya Corp
TSE:7741
7.1T JPY 8.5 35.6 23.9 28.8
CH
Alcon AG
SIX:ALC
37.9B CHF 4.2 35.7 17.6 34.1
DK
Coloplast A/S
CSE:COLO B
179B DKK 6.6 35.5 22.8 26.8
US
Align Technology Inc
NASDAQ:ALGN
16.1B USD 4.1 36.4 18.4 22.1
KR
HLB Inc
KOSDAQ:028300
10.5T KRW 202.1 -56.5 -87 -82.1
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
51.1B CNY 11.5 27.6 24 24
US
Lantheus Holdings Inc
NASDAQ:LNTH
6.5B USD 4.4 15.3 10.6 12
CA
Bausch + Lomb Corp
NYSE:BLCO
6.4B USD 1.4 -17.3 16.7 56
US
Merit Medical Systems Inc
NASDAQ:MMSI
5.7B USD 4.3 47.6 23.7 38.9
UK
ConvaTec Group PLC
LSE:CTEC
4.6B GBP 2.6 37.2 264.5 462.1
P/E Multiple
Earnings Growth PEG
HK
H
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Average P/E: 33.9
Negative Multiple: -13.6 		N/A N/A
JP
Hoya Corp
TSE:7741
35.6
15%
2.4
CH
Alcon AG
SIX:ALC
35.7
27%
1.3
DK
Coloplast A/S
CSE:COLO B
35.5
15%
2.4
US
Align Technology Inc
NASDAQ:ALGN
36.4
26%
1.4
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -56.5 N/A N/A
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
27.6
24%
1.1
US
Lantheus Holdings Inc
NASDAQ:LNTH
15.3
19%
0.8
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -17.3 N/A N/A
US
Merit Medical Systems Inc
NASDAQ:MMSI
47.6
37%
1.3
UK
ConvaTec Group PLC
LSE:CTEC
37.2
46%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
H
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Average EV/EBITDA: 46.9
Negative Multiple: -6.3 		N/A N/A
JP
Hoya Corp
TSE:7741
23.9
15%
1.6
CH
Alcon AG
SIX:ALC
17.6
10%
1.8
DK
Coloplast A/S
CSE:COLO B
22.8
11%
2.1
US
Align Technology Inc
NASDAQ:ALGN
18.4
15%
1.2
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -87 N/A N/A
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
24
27%
0.9
US
Lantheus Holdings Inc
NASDAQ:LNTH
10.6
11%
1
CA
Bausch + Lomb Corp
NYSE:BLCO
16.7
22%
0.8
US
Merit Medical Systems Inc
NASDAQ:MMSI
23.7
22%
1.1
UK
ConvaTec Group PLC
LSE:CTEC
264.5
12%
22

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 215,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.